Antibody Response to COVID-19 Booster Vaccination in Healthcare Workers

Frontiers in Immunology

Laura Zoppini¹  Silvia Renica²  Valentina Panetta³  Michele Senatore⁴  Massimo Puoti⁵  Marco Bosio⁵  Michaela Bertuzzi⁷  Chiara Vismara⁷  Silvia Nerini Molteni⁷  Daniela Campisi⁷  Matteo Maggi⁸  Alice Schianchi⁸  Tommaso Conti⁸  Stefano D’Onghia⁸  Alessandra Romandini⁸  Stefano Agliardi⁸  Arianna Pani⁸  Paolo A. Schenardi⁸  Oscar M. Gagliardi⁸  Gianluca Gazzaniga⁸  Simona Giroldi⁹  Francesco Scaglione^1,10  Marco Merli^1,11  Mauro Moreno^1,11 

[1] Risk Control in Data Management, Azienda Socio Sanitaria Territoriale (ASST) Grande Ospedale Metropolitano Niguarda, Milan, Italy;Training, Rome, Italy;;Biostatistics Office, L’altrastatistica srl – Consultancy &Chemical-Clinical Analysis Unit, Laboratory Medicine Department, Niguarda Hospital, Milan, Italy;Healthcare Management Department, Azienda Socio Sanitaria Territoriale (ASST) Grande Ospedale Metropolitano Niguarda,Milan, Italy;Infectious Diseases Unit, Azienda Socio Sanitaria Territoriale (ASST) Grande Ospedale Metropolitano Niguarda, Milan, Italy;Microbiology Unit, Laboratory Medicine Department, Niguarda Hospital, Milan, Italy;Oncology and Hemato-Oncology Department, Università degli Studi di Milano, Milan, Italy;;Quality &School of Medicine and Surgery, Università degli Studi di Milano Bicocca, Milan, Italy;Socio-sanitary Direction, Azienda Socio Sanitaria Territoriale (ASST) Grande Ospedale Metropolitano Niguarda, Milan, Italy;

关键词: COVID-19;    SARS-CoV-2;    vaccine booster;    healthcare workers (HCWs);    antibody response;   

DOI  :  10.3389/fimmu.2022.872667

来源: DOAJ

【 摘 要 】

ObjectiveTo evaluate the mean increase of anti-S IgG antibody titer between the basal, pre-booster level to the titer assessed 14 days after the booster dose of BNT162b2.Patients and MethodsThe RENAISSANCE study is an observational, longitudinal, prospective, population-based study, conducted on healthcare workers of Niguarda Hospital in Milan, Italy who received a BNT162b2 booster dose at least 180 days after their second dose or after positivity for SARS-CoV-2 and accepted to take part in the study. The RENAISSANCE study was conducted from January 1, 2021 through December 28, 2021.Findings1,738 subjects were enrolled among healthcare workers registered for the booster administration at our hospital. Overall, 0.4% of subjects were seronegative at the pre-booster evaluation, and 1 subject had a titer equal to 50 AU/ml: none of the evaluated subjects was seronegative after the booster dose. Thus, the efficacy of the booster in our population was universal. Mean increase of pre- to post-booster titer was more significant in subjects who never had SARS-CoV-2 (44 times CI 95% 42-46) compared to those who had it, before (33 times, CI 95% 13-70) or after the first vaccination cycle (12 times, CI 95% 11-14). Differently from sex, age and pre-booster titers affected the post-booster antibody response. Nevertheless, the post-booster titer was very similar in all subgroups, and independent of a prior exposure to SARS-CoV-2, pre-booster titer, sex or age.ConclusionOur study shows a potent universal antibody response of the booster dose of BNT162b2, regardless of pre-booster vaccine seronegativity.

【 授权许可】

Unknown